Aluminium

證據等級: L5

預測適應症: 10 個

Aluminium: From Antacid/Mucosal Protectant to Peptic Ulcer Disease

One-Sentence Summary

Aluminium (DrugBank DB01370) is the active metal component of established gastrointestinal mucosal protective agents — including sucralfate (aluminium sucrose sulfate) and aluminium hydroxide antacids — which have been used internationally for upper gastrointestinal conditions for decades, but are not currently registered on the Australian Register of Therapeutic Goods (ARTG) under this DrugBank entry.

The TxGNN model predicts it may be effective for Peptic Ulcer Disease (PUD), with 4 clinical trials and 20 publications currently supporting this direction.

Notably, the evidence base largely validates the well-established historical use of aluminium-containing formulations in PUD management; the key question for this evaluation is whether the evidence base is sufficient to support formal TGA registration of a specific aluminium-based preparation in Australia.

Quick Overview

Item	Content
Original Indication	No registered indication (not currently marketed in Australia)
Predicted New Indication	Peptic Ulcer Disease
TxGNN Prediction Score	97.34%
Evidence Level	L2
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available from DrugBank for this entry. However, based on the well-characterised pharmacology of aluminium-based compounds documented in the supporting literature, several established mechanisms directly explain the predicted association with peptic ulcer disease.

Aluminium compounds exert mucosal protective and acid-neutralising effects through multiple complementary pathways. Sucralfate — a basic aluminium salt of sulphated sucrose — polymerises in the acidic gastric environment (pH < 4) to form a viscous, adherent gel that binds to negatively charged proteins at the ulcer site, creating a physical protective barrier lasting more than six hours. In parallel, aluminium ions stimulate local prostaglandin synthesis and enhance mucosal bicarbonate secretion, providing a cytoprotective effect that extends beyond simple acid buffering. Aluminium hydroxide antacids act through a distinct but complementary mechanism, directly neutralising gastric acid and raising intragastric pH to 3.5–4.5, which concurrently reduces pepsin proteolytic activity and decreases mucosal irritation.

Peptic ulcer disease is fundamentally characterised by disruption of the gastroduodenal mucosal barrier combined with excess acid-pepsin exposure — precisely the pathophysiological conditions that aluminium-based compounds are mechanistically suited to address. The strong TxGNN prediction score (97.34%) is highly consistent with decades of clinical use of sucralfate and aluminium hydroxide antacids for both gastric and duodenal ulcer healing internationally, including regulatory approvals in the United States, Japan, and Europe. The outstanding clinical questions are not whether a mechanistic rationale exists, but rather whether a specific modern aluminium-based formulation offers advantages over established first-line treatments (proton pump inhibitors, H. pylori eradication therapy) and whether a clear regulatory pathway to TGA registration is feasible.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT07310927	Phase 2/3	Recruiting	140	Most directly relevant ongoing RCT: directly compares sucralfate (an aluminium compound) against alginate for symptomatic relief of GERD and ulcer symptoms in combination with PPIs — results will directly inform evidence level for aluminium-based compounds in upper GI mucosal disease
NCT01964131	Phase 1	Completed	34	Bioequivalence study of D961H (aluminium-based formulation) capsule vs sachet assessed by intragastric pH monitoring and pharmacokinetics in Japanese healthy male subjects; provides pharmacodynamic reference data for aluminium-based preparations
NCT06526455	Phase 4	Not Yet Recruiting	196	Multicentre double-blind RCT comparing vonorasan vs esomeprazole for post-ESD ulcer healing, with aluminium phosphate gel used as an adjunct intervention; aluminium compound is a secondary rather than primary study drug, limiting direct applicability
NCT00854776	N/A	Unknown	300	Observational study examining PUD incidence in ischaemic heart disease patients on aspirin/clopidogrel ± proton pump inhibitor; provides epidemiological context for antiplatelet-associated peptic ulcer burden but is not an aluminium treatment intervention trial

Literature Evidence

PMID	Year	Type	Journal	Key Findings
7590572	1995	Clinical Study	Hepato-Gastroenterology	Single-centre RCT in 50 endoscopically verified duodenal/gastric ulcer patients comparing sucralfate effervescent tablet vs granular formulation (2g twice daily); includes serial monitoring of serum aluminium concentrations — key safety data point
789170	1975	Clinical Study	Gastroenterologia Japonica	Multi-institutional double-blind controlled study in 302 gastric ulcer patients comparing N-acetyl-L-glutamine aluminium complex, basic aluminium sucrose sulfate, and placebo over 12 weeks; demonstrates significant ulcer healing advantage over placebo
4571693	1973	Clinical Trial	Drug and Therapeutics Bulletin	Early clinical trial of Caved-S (aluminium-containing compound) and Ulcedal for peptic ulcer — among the earliest controlled clinical evidence for aluminium-based PUD treatment
6764389	1982	Review	Clinical Pharmacy	Comprehensive pharmacology review of sucralfate for PUD: mucosal barrier formation, local acid neutralisation without systemic pH change, pepsin inhibition, and bile salt adsorption; foundational reference for the mechanism of aluminium-based mucosal protection
6368184	1984	Review	Drugs	Definitive pharmacodynamics review of sucralfate: controlled trials demonstrating efficacy equivalent to H2-antagonists in healing duodenal and gastric ulcers over 4–8 weeks at 1g four times daily; minimal systemic absorption (3–5%) noted
38192	1979	Review	Gut	Critical reappraisal of antacid therapy in PUD: intensive aluminium-containing antacid regimens shown to be effective for duodenal ulcer healing and prevention of stress ulcer haemorrhage, comparable in efficacy to cimetidine
8912126	1996	Clinical Study	Journal of Gastroenterology and Hepatology	Prospective study measuring aluminium accumulation in liver tissue and cerebrospinal fluid in 15 patients each taking sucralfate or aluminium hydroxide for one month; documents measurable hepatic and CSF aluminium deposition — critical safety reference for systemic exposure
2865092	1985	Review	Digestive Diseases and Sciences	Pharmacological classification of anti-ulcer drugs by mechanism; aluminium-based agents categorised as cytoprotective/mucosal protectants, distinct from antisecretory agents — contextualises the role of aluminium compounds within the PUD treatment armamentarium
6095662	1984	Review	American Journal of Medicine	Practical review of PUD pharmacotherapy including sucralfate and H2-antagonists; highlights that aluminium-containing agents (sucralfate, antacids) were among the four main drug classes available in the US at that time
2401189	1990	Clinical Study	Drugs Under Experimental and Clinical Research	Retrospective study in 267 paediatric patients with peptic symptoms including assessment of aluminium-containing compounds; relevant for understanding PUD management across age groups and paediatric safety considerations

Australia Market Information

Aluminium (DrugBank DB01370) is not currently registered on the Australian Register of Therapeutic Goods (ARTG). No TGA-approved products exist under this DrugBank entry in Australia.

Aluminium-containing formulations with established PUD use internationally (e.g., sucralfate, aluminium hydroxide antacid gels) would each require a separate TGA registration pathway as distinct therapeutic goods before any PUD indication could be formally approved in Australia.

Safety Considerations

Key safety signal — aluminium systemic accumulation: Short-course oral therapy with sucralfate or aluminium hydroxide antacids is generally considered safe in patients with normal renal function. However, PMID 8912126 documents measurable aluminium deposition in liver tissue and cerebrospinal fluid following standard one-month therapeutic courses. Risk is substantially elevated in renally impaired patients, in whom aluminium clearance is reduced. Renal function monitoring is warranted prior to initiation and during prolonged courses.

Important adverse signal — aluminium as a contact allergen (Rank 3 prediction): Evidence retrieved for the dermatitis prediction indicates that aluminium can cause rather than treat dermatitis. Aluminium-adsorbed vaccines are associated with injection-site granulomas and Type IV delayed hypersensitivity reactions; aluminium in sunscreens and antiperspirants can induce allergic contact dermatitis, particularly in previously sensitised individuals (PMID 33797096 — systematic review and meta-analysis). This is a clinically important adverse signal for any topical or parenteral aluminium-containing formulation and should be factored into formulation selection and patient screening.

For complete safety information on any specific aluminium-based formulation, please refer to the relevant Product Information (PI) for that preparation.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction for peptic ulcer disease is strongly supported by decades of clinical and pharmacological evidence for aluminium-based compounds, and the mechanistic basis for mucosal protection and acid neutralisation is well-characterised in the published literature. However, aluminium-based preparations for PUD are not currently registered on the ARTG, the supporting evidence largely pre-dates modern regulatory standards, and first-line PUD therapy has evolved significantly (PPIs, H. pylori eradication) since the period when aluminium-based agents were most widely studied.

To proceed, the following is needed:

Formulation specification: Identify the precise aluminium-containing formulation intended for evaluation (sucralfate vs aluminium hydroxide vs aluminium phosphate gel), as clinical evidence profiles, safety data, and regulatory requirements differ substantially between forms
Formal MOA data: Retrieve complete mechanism of action documentation from DrugBank or equivalent authoritative source to support the regulatory dossier
Comparative efficacy assessment: Evaluate evidence relative to contemporary Australian first-line PUD management (PPI therapy, H. pylori eradication per current gastroenterological guidelines), given the predominantly historical evidence base
Safety monitoring plan: Develop a renal function monitoring protocol addressing aluminium absorption risk, particularly for renally impaired patients, elderly populations, and extended-treatment courses; reference PMID 8912126 for aluminium accumulation baseline data
Adverse signal management: Formally risk-stratify the contact allergy/dermatitis adverse signal for the intended route of administration; implement pre-treatment aluminium sensitisation screening if a topical formulation is being considered
TGA regulatory pathway: Engage with the TGA to identify the most appropriate registration pathway (e.g., new chemical entity vs. established substance with new indication vs. bibliographic application) for the intended formulation and indication

⚠️ Disclaimer: This report is for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before clinical application. All content should be interpreted in conjunction with TGA-approved Product Information and current Australian clinical practice guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.